Personalis Inc
Research Personalis Inc (PSNL) on Bullrun: market cap USD 1.83B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPSNL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 1.83B
- Financial periodQ2 2026
- RevenueUSD 22.36M
- Net income-USD 31.68M
- Free cash flow-USD 29.55M
- Gross margin21.2%
Valuation Snapshot
latest market cap is USD 1.83B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 69.65M | -USD 81.27M | -USD 79.45M | 22.7% | -0.91 | USD 124.25M | USD 39.95M | USD 261.19M |
| FY2024 | USD 84.61M | -USD 81.28M | -USD 46.75M | 31.7% | -1.37 | USD 91.42M | USD 44.25M | USD 202.96M |
| FY2023 | USD 73.48M | -USD 108.30M | -USD 67.17M | 24.8% | -2.25 | USD 56.98M | USD 47.73M | USD 129.44M |
| FY2022 | USD 65.05M | -USD 113.32M | -USD 120.13M | 20.5% | -2.48 | USD 89.13M | USD 58.22M | USD 218.14M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.83B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 815.71M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 492.29M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 102.97M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 91.02M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 640.79M | n/a | n/a | n/a |
About Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Personalis Inc's market cap?
Personalis Inc's market capitalization is USD 1.83B.
What does Personalis Inc do?
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.